Comparative Study of Anaconda System Use Versus Conventional Sedation in COVID-19 Patients.

Comparative Study of Sedative Requirement Using Sevoflurane With Anaconda Device Versus Conventional Sedation in Patients With COVID-19

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06208592

Enrollment

Registered

2024-01-17

Start date

2020-05-30

Completion date

2020-11-06

Last updated

2024-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, Respiratory Failure

Keywords

sedatives, acute kidney injury, SARS-CoV-2, mechanical ventilation

Brief summary

At the beginning of 2020, a global alert emerged which saturated intensive care units due to COVID-19 worldwide. This caused a need for mechanical ventilation due to atypical pneumonias that had a rapid evolution and respiratory failure; therefore the consumption of sedative agents in the intensive care units escalated. Suboptimal sedation in the intensive care unit, increases the adverse effects, costs, and morbidity. For the time being, they focus on the use of intravenous agents such as propofol or dexmedetomidine, which are associated with tolerance, withdrawal, delirium, and hemodynamic effects. Consequently, the need arises to maximize availability and effectiveness, which is why the intervention of the ANACONDA conservation device is carried out, which works with a heat and humidity exchange filter capable of administering isoflurane or sevoflurane with an efficiency of 90%.

Detailed description

Analyze the difference in intravenous sedation requirements in patients with COVID-19. Patients who were assisted by a mechanical ventilator with sevoflurane versus conventional sedation.

Interventions

DEVICESevoflurane with AnaConDa

Sevoflurane administered with AnaConDa device

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

27 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Adult patients with confirmed COVI-19 infection and assited with mechanical ventilation who entered critical care department.

Exclusion criteria

* Tranfers to a different hospital. * Death within the first 24 hours of hospital stay.

Design outcomes

Primary

Measure	Time frame	Description
Intravenous sedation requirements	7 days	Amount of intravenous sedation required

Secondary

Measure	Time frame	Description
Delirium	Hospital stay (up to 30 days)	Number of patients that suffered delirium
Acute kidney injury	Hospital stay (up to 30 days)	Number of patients that suffered delirium
VAP	Hospital stay (up to 30 days)	Number of patients that suffered ventilation acquired pneumonia

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026